Lifestyle

Clinical Articles iconClinical Articles

With obesity demonstrating mortality rates comparable to cigarette smoking and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches. Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.

Upcoming Healthed Webcast

Tune in for "Gallbladder – When surgery is or is not needed" lecture

Tuesday 26th May, 7pm - 9pm AEST

Speaker

Dr David Yeo

Specialist Upper GI, Hepatobiliary and Bariatric Surgeon; Chris O’Brien Lifehouse, RPA and St George Hospitals

In this talk, surgeon, Dr David Yeo will answer these and many other real-world questions related to this common condition and provide an update on the latest recommendations for the assessment, investigation and management of gallbladder disease.